Anti-Human IL-1 beta/IL-1F2 Reference Antibody (Firsekibart, RUO) (HF943096)

Name: Anti-Human IL-1 beta/IL-1F2 Reference Antibody (Firsekibart, RUO)
Brand: abinScience
SKU: HF943096
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HF943096
Descripción	firsekibart (HF943096) is a research-grade recombinant antibody targeting IL1B/IL1F2. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG4, lambda2
Especies	Human
Objetivo	IL1B/IL1F2
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Número de acceso	P01584
Forma	Liquid
Reconstitución	Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Envío	In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	2981430-39-9
Fondo	Interleukin-1 beta (IL1B/IL1F2) is a ~30 kDa protein. Potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells. Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6. IL1B is the therapeutic target of canakinumab (Ilaris). 1. Tominaga, K. et al. (2000) International immunology 12, 151-60. PMID: 10653850 2. Nakahara, H. et al. (2003) Arthritis and rheumatism 48, 1521-9. PMID: 12794819 3. LaRock, CN. et al. (2016) Science immunology 1. PMID: 28331908 4. Van Damme, J. et al. (1985) Nature 314, 266-8. PMID: 3920526 5. Tian, XX. et al. (2021) International endodontic journal 54, 916-925. PMID: 33377178 6. Xia, S. et al. (2021) Nature 593, 607-611. PMID: 33883744
Nota	For research use only. Not suitable for clinical or therapeutic use.